Palisade Bio, Inc. (PALI)
$
0.81
+0.05 (6.17%)
Key metrics
Financial statements
Free cash flow per share
-2.3659
Market cap
3.3 Million
Price to sales ratio
0
Debt to equity
0.0109
Current ratio
2.8401
Income quality
0.8634
Average inventory
0
ROE
-1.7891
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of oral therapies designed to address severe diseases linked to the deterioration of the mucosal barrier in the gastrointestinal tract. The company's lead candidate, LB1148, is an oral liquid formulation that functions as a digestive enzyme inhibitor, aimed at minimizing digestive enzyme activity and maintaining gut integrity during periods of intestinal stress caused by factors such as reduced blood flow, infections, or surgical interventions. The company incurred an income tax expense of $0.00 indicating its tax obligations. Additionally, the company reported selling, general, and administrative expenses of $5,796,000.00 reflecting its operational overhead costs. With a focus on niche markets, the company achieved a revenue of $0.00. Its EBITDA stands at -$14,859,000.00 serving as a key measure of operational profitability. The company, founded in 2005, has established its headquarters in Carlsbad, California, and its stock is identified with the symbol 'PALI' in the market. The stock is affordable at $0.81 making it an appealing option for budget-conscious investors. It has a high average trading volume of 385,920.00 which indicates strong liquidity in the market. With a market capitalization of $3,870,090.00 the company is classified as a small-cap player, which adds to its dynamic profile. Positioned as a key player in the Biotechnology industry, the company contributes significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field. This combination of affordability, liquidity, and market presence underscores the potential for investors looking for opportunities in emerging biotech solutions.
Is Palisade Bio, Inc. (PALI) a good investment?
Investing in Palisade Bio, Inc. (PALI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Palisade Bio, Inc. (PALI)'s stock forecast?
Analysts predict Palisade Bio, Inc. stock to fluctuate between $0.60 (low) and $5.15 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Palisade Bio, Inc.'s market capitalization?
As of 2025-05-23, Palisade Bio, Inc.'s market cap is $3,870,090, based on 4,795,650 outstanding shares.
How does Palisade Bio, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Palisade Bio, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Palisade Bio, Inc. (PALI) stock?
To buy Palisade Bio, Inc. (PALI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PALI. Place an order (Market, Limit, etc.).
What is the best time to invest in Palisade Bio, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Palisade Bio, Inc. stock ever split?
Palisade Bio, Inc.'s last stock split was 1:15 on 2024-04-08.
How did Palisade Bio, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.48 | Growth: 37.78%.
Where can I find Palisade Bio, Inc.'s investor relations reports?
Visit https://www.palisadebio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Palisade Bio, Inc.?
You can explore historical data from here
What is the all-time high and low for Palisade Bio, Inc. stock?
All-time high: $8,182.50 (2021-04-28) | All-time low: $0.60 (2025-04-04).
What are the key trends affecting Palisade Bio, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Access here Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced positive topline results from its completed Phase 1 studies of PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn's disease (FSCD) and moderate to severe ulcerative colitis (UC). Additionally, the Company announced the release of a Virtual Investor “What This Means” segment to discuss the topline data, which is now available here.
globenewswire.com
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients with ulcerative colitis (UC). The presented data highlighted the efficacy and safety profile of PALI-2108 in a mouse model of colitis, with a particular focus on its impact on PDE4B expression, cAMP levels, and TNF-α suppression as well as predicting efficacious PALI-0008 levels in patients.
globenewswire.com
Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108
globenewswire.com
Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108
globenewswire.com
PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW
globenewswire.com
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC)
globenewswire.com
Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108
See all news
